Advertisement

Economic Considerations in Medical Biotechnology

  • Amit S. PatelEmail author
  • Kartick P. Shirur
Chapter

Abstract

New products, that are often more expensive than existing treatments, are launched every year to treat various diseases. Patients, providers, and payers desire better outcomes at lower, controllable and more predictable costs. In this chapter, we demonstrate, using examples, how the value of a new product can be attributed to different factors like improved efficacy, safety and cost-saving. Then we describe the various pharmacoeconomic analyses used to identify and evaluate the value of new therapies. We discuss the various costs that are considered in these analyses (direct, indirect, intangible, and opportunity costs), and different types of analyses that are often utilized (cost of illness, cost-minimization, cost-benefit, cost-effectiveness, and cost-utility analyses) along with examples. Payers and providers may use the results of such analyses to make formulary and coverage decisions. Finally, we discuss steps taken by some states in the US to control drug pricing and reimbursement, and the potential of recently launched biosimilars to lower health care costs spent on biological products.

Keywords

Value Pharmacoeconomics Cost of illness Cost-minimization analysis Cost-benefit analysis Cost-effectiveness analysis Cost-utility analysis Biosimilars 

References

  1. Argenta C, Ferreira MA, Sander GB, Moreira LB (2011) Short-term therapy with enoxaparin or unfractionated heparin for venous thromboembolism in hospitalized patients: utilization study and cost-minimization analysis. Value Health 14:S89–S92CrossRefGoogle Scholar
  2. Arrieta A, Page TF, Veledar E, Nasir K (2017a) Economic evaluation of PCSK9 inhibitors in reducing cardiovascular risk from health system and private payer perspectives. PLoS One 12(1):e0169761CrossRefGoogle Scholar
  3. Arrieta A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K (2017b) Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: insights derived from the FOURIER trial. JAMA Cardiol 2(12):1369–1374CrossRefGoogle Scholar
  4. Bootman JL, Townsend JT, McGhan WF (1991) Principles of pharmacoeconomics. Harvey Whitney Books, CincinnatiGoogle Scholar
  5. Chang K, Nash D (1998) The role of pharmacoeconomic evaluations in disease management. PharmacoEconomics 14(1):11–17CrossRefGoogle Scholar
  6. Collins AJ, Li S, Ebben J, Ma JZ, Manning W (2000) Hematocrit levels and associated Medicare expenditures. Am J Kidney Dis 36(2):282–293CrossRefGoogle Scholar
  7. Coyle D, Lee K, Laupacis A, Fergusson D (1999) Economic analysis of erythropoietin in surgery. Canadian Coordinating Office for Health Technology Assessment, OttawaGoogle Scholar
  8. Goulart B, Ramsey S (2011) A trial-based assessment of the utility of Bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Value Health 14:836–845CrossRefGoogle Scholar
  9. Grauer DW, Lee J, Odom TD, Osterhaus JT, Sanchez LA (2003) Pharmacoeconomics and outcomes: applications for patient care, 2nd edn. American College of Clinical Pharmacy, Kansas CityGoogle Scholar
  10. Hwang TJ, Kesselheim AS, Sarpatwari A (2017) Value-based pricing and state reform of prescription drug costs. JAMA 318(7):609–610CrossRefGoogle Scholar
  11. Joshnson N, Nash D (eds) (1996) The role of pharmacoeconomics in outcomes management. American Hospital Publishing, ChicagoGoogle Scholar
  12. Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, Tice JA, Guzman D, Bibbins-Domingo K (2016) Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA 316(7):743–753CrossRefGoogle Scholar
  13. Kazi DS, Penko J, Coxson PG, Moran AE, Ollendorf DA, Tice JA, Bibbins-Domingo K (2017) Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial. JAMA 318(8):748–750CrossRefGoogle Scholar
  14. Sarpatwari A, Avorn J, Kesselheim AS (2016) State initiatives to control medication costs — can transparency legislation help? N Engl J Med 374:2301–2304CrossRefGoogle Scholar
  15. Segel JE (2006) Cost-of-illness studies—a primer, RTI-UNC center of excellence in health promotion economics, Jan 2006. http://www.rti.org/pubs/coi_primer.pdf Google Scholar
  16. Szcus TD, Schneeweiss S (2003) Pharmacoeconomics and its role in the growth of the biotechnology industry. J Commer Biotechnol 10(2):111–122CrossRefGoogle Scholar
  17. Townsend R (1987) Postmarketing drug research and development. Drug Intell Clin Pharm 21(1pt 2):134–136CrossRefGoogle Scholar
  18. Walkom E, Robertson J, Newby D, Pillay T (2006) The role of pharmacoeconomics in formulary decision-making: considerations for hospital and managed care pharmacy and therapeutics committees. Formulary 41:374–386Google Scholar

Suggested Reading

    Pharmacoeconomic Methods and Pricing Issues

    1. Bonk RJ (1999) Pharmacoeconomics in perspective. Pharmaceutical Products Press, New YorkGoogle Scholar
    2. Drummond MF, O’Brien BJ, Stoddart GL, Torrance GW (1997) Methods for the economic evaluation of health care programmes, 2nd edn. Oxford University Press, OxfordGoogle Scholar
    3. Kolassa EM (1997) Elements of pharmaceutical pricing. Pharmaceutical Products Press, New YorkCrossRefGoogle Scholar

    Pharmacoeconomics of Biotechnology Drugs

    1. Dana WJ, Farthing K (1998) The pharmacoeconomics of high-cost biotechnology products. Pharm Pract Manag Q 18(2):23–31PubMedGoogle Scholar
    2. Hui JW, Yee GC (1998a) Pharmacoeconomics of biotechnology drugs (part 1 of 2). J Am Pharm Assoc 38(1):93–97Google Scholar
    3. Hui JW, Yee GC (1998) Pharmacoeconomics of biotechnology drugs (part 2 of 2). J Am Pharm Assoc 38(2):231–233Google Scholar
    4. Reeder CE (1995) Pharmacoeconomics and health care outcomes management: focus on biotechnology (special supplement). Am J Health Syst Pharm 52:19,S4):S1–19,S4)S28Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of PharmacyUniversity of MississippiOxfordUSA
  2. 2.Department of PharmacyMedical Marketing Economics, LLCOxfordUSA
  3. 3.Medical Marketing Economics, LLCOxfordUSA

Personalised recommendations